HERO

Grand Rounds October 28, 2022: The HERO (Healthcare Worker Exposure Response & Outcomes) Program: An Online Community to Support Observational Studies, Randomized Trials, and Long-Term Safety Surveillance (Emily O’Brien, PhD, FAHA; Russell Rothman, MD, MPP)

Posted on by terren.green@duke.edu

Speakers

Emily O’Brien, PhD, FAHA
Associate Professor
Duke Clinical Research Institute
Duke University School of Medicine
Department of Population Health Sciences

Russell Rothman, MD, MPP
Senior Vice President, Population and Public Health
Director, Vanderbilt Institute for Medicine and Public Health
Vanderbilt University Medical Center

 

 

Keywords

HERO Registry; HERO TOGETHER; Hydroxychloroquine; COVID-19; PCORI; PCORnet

 

Key Points

  • On March 21, 2020, in response to the COVID-19 pandemic, PCORI contacted leadership at Duke Clinical Research Institute and PCORnet and a decision was made to focus on the space of healthcare workers. The HERO Program was fully approved and began recruiting participants on April 22, 2020.
  • The HERO Registry aimed to create a diverse virtual community of healthcare workers and their families and communities, ready for future COVID-19 research.
  • The HERO Registry explored topics that mattered most to participants and found these topics changed with time. Important issues early on included COVID-19’s effects on the workplace, vaccine access and willingness, and impact on home life. Later, burnout and lack of appreciation and support became larger issues.
  • The first trial undertaken by the HERO Program, HERO-HCQ, evaluated the efficacy of hydroxychloroquine (HCQ) to prevent COVID-19 in healthcare workers. Over 1300 participants were recruited from the HERO Registry. No statistically significant benefit was found.
  • The HERO TOGETHER study leveraged the HERO Registry to estimate real-world incidence of safety events among vaccinated individuals. The most common safety events reported included non-hospitalized arthritis/arthralgia and non-hospitalized non-anaphylactic allergic reaction.

Learn more

On the HERO Program website.

Discussion Themes

– The HERO Registry survey collected a large broad range of information. Participant feedback revealed that shorter more targeted surveys focusing on the most high-value information may have been less burdensome for participants..

– The creative multi-faceted approach to recruitment that includes diverse stakeholder engagement could be successful in creating research registries for other important health issues. .

Tags

#pctGR, @Collaboratory1

October 26, 2022: In This Friday’s PCT Grand Rounds, an Update on the HERO Registry

Posted on by Damon Seils

Headshots of Dr. Emily O'Brien an Dr. Russell RothmanIn this Friday’s PCT Grand Rounds, Emily O’Brien of Duke University and Russell Rothman of Vanderbilt University will present “The HERO (Healthcare Worker Exposure Response & Outcomes) Program: An Online Community to Support Observational Studies, Randomized Trials, and Long-Term Safety Surveillance.” The Grand Rounds session will be held on Friday, October 28, 2022, at 1:00 pm eastern.

O’Brien is an associate professor in population health sciences at Duke University and a cochair of the NIH Collaboratory’s Patient-Centered Outcomes Core. Rothman is senior vice president for population and public health and director of the Vanderbilt Institute for Medicine and Public Health at Vanderbilt University Medical Center.

Join the online meeting.

May 3, 2021: HERO Registry and HERO-TOGETHER Expand Beyond Healthcare Workers

Posted on by Damon Seils

Logo for the Healthcare Worker Exposure Response & Outcomes (HERO) project.The Healthcare Worker Exposure Response & Outcomes (HERO) Registry and the HERO-TOGETHER study are now open to anyone who lives, works, or interacts with healthcare workers in their households or anyone in the surrounding community. The HERO program enables participants to share their experiences after receiving a COVID-19 vaccine, contribute to the science, and help to build vaccine confidence over time.

HERO-TOGETHER is a nationwide paid study focused on the long-term impact of the COVID-19 vaccines. Healthcare workers around the country have already signed up. Now all healthcare workers and anyone who lives, works, or interacts with them are invited to join the study. Participants answer brief surveys about how they’re feeling and any health changes since receiving a COVID-19 vaccine. Participants receive information back and up to $200 compensation for their time. Sign up here.

View the NIH Collaboratory’s recent COVID-19 Grand Rounds session on HERO-TOGETHER.

 

March 19, 2021: HERO-Learning Together about Vaccines for SARS-CoV-2 (Emily O’Brien, PhD; Robert Califf, MD)

Posted on by Gina Uhlenbrauck

Speakers

Emily O’Brien, PhD, FAHA
Associate Professor
Duke Clinical Research Institute
Duke University School of Medicine
 
Robert M. Califf, MD, MACC
Head of Clinical Policy and Strategy
Verily Life Sciences and Google Health

Topic

HERO-Learning Together about Vaccines for SARS-CoV-2

Keywords

COVID-19; Vaccine confidence; Side effects; Postmarketing surveillance; Long-term vaccine safety; Virus variants; PCORI; HERO Registry

Key Points

  • In the United States to date, more than 100 million doses of COVID-19 vaccine have been administered. Yet there remains concern about the increase in variants of the coronavirus.
  • Postmarket evidence generation around COVID-19 vaccines is critically important to understanding the long-term safety of vaccines and building confidence around their use.
  • A “pod” is the group of people you live with or relate to as family and have regular household contact with at least once per week for the past 3 months.

Discussion Themes

What does it mean to be a “safe vaccine”?

We’re still learning about how families are navigating the psychosocial aspects of this pandemic.

Over time, manual processes will be replaced by algorithms and automated systems. But we need to develop digital technologies that support human interactions in health.

What will be the key issues around COVID-19 in 2022?

HERO-TOGETHER is a paid observational research study for people aged 18 and older working in healthcare who have received a COVID-19 vaccine. Eligible participants include anyone who works in a setting where people receive healthcare. Read more about the HERO Program and how to join the registry.

Tags

#pctGR, #HEROTOGETHER, @Collaboratory1, @heroesresearch

March 16, 2021: Drs. Emily O’Brien and Robert Califf Will Discuss HERO Collaboration in Special COVID-19 Grand Rounds

Posted on by Damon Seils

In this week’s COVID-19 Grand Rounds session, Dr. Emily O’Brien of Duke University and Dr. Robert Califf of Verily Life Sciences and Google Health will present “HERO—Learning Together About Vaccines for SARS-CoV-2.” The Duke Clinical Research Institute and Verily are using the Healthcare Worker Exposure Response & Outcomes (HERO) Registry and its community of participants and researchers to gain long-term insights about the COVID-19 vaccine developed by Pfizer and BioNTech, including real-world safety data.

The Grand Rounds session will be held on Friday, March 19 at 1:00 pm eastern. Join the online meeting.

The NIH Collaboratory Coordinating Center is using its popular Grand Rounds platform to share late-breaking research and promote resources in support of clinical researchers affected by the COVID-19 public health emergency.

For previous COVID-19 Grand Rounds, and more news and resources related to the COVID-19 public health emergency, see the COVID-19 Resources page.

January 6, 2021: NIH Collaboratory COVID-19 Grand Rounds Continues With HERO-TOGETHER Long-Term Safety Study

Posted on by Damon Seils

Dr. Emily O'BrienIn this week’s COVID-19 Grand Rounds session, Dr. Emily O’Brien of Duke University will present “HERO-Together: Building Vaccine Confidence With Long-Term Outcomes Data.” The Grand Rounds session will be held on Friday, January 8, at 1:00 pm eastern. Join the online meeting.

HERO-Together is a long-term safety study of the COVID-19 vaccine developed by Pfizer and BioNTech. In the study, the Duke Clinical Research Institute (DCRI) and Verily, with funding from Pfizer, are using the HERO Registry to gain long-term insights about the vaccine by following vaccinated healthcare workers for 2 years to assess their experiences after receiving the vaccine.

The NIH Collaboratory Coordinating Center is using its popular Grand Rounds platform to share late-breaking research and promote resources in support of clinical researchers affected by the COVID-19 public health emergency.

For previous COVID-19 Grand Rounds, and more news and resources related to the COVID-19 public health emergency, see the COVID-19 Resources page.

Grand Rounds January 8: HERO-Together: Building Vaccine Confidence With Long-Term Outcomes Data

Speaker:

Emily O’Brien, PhD, FAHA
Associate Professor
Duke Clinical Research Institute
Duke University School of Medicine
Department of Population Health Sciences

Topic: HERO-Together: Building Vaccine Confidence With Long-Term Outcomes Data
Date: Friday, January 8, 2021, 1:00-2:00 p.m. ET

Meeting Info: To check whether you have the appropriate players installed for UCF (Universal Communications Format) rich media files, go to https://dukemed.webex.com/dukemed/systemdiagnosis.php.

To join the online meeting:
Go to https://dukemed.webex.com/dukemed/j.php?MTID=m60b64f1826bed9d8f0b16c759c4fdcb0

You must log in to the URL first.
Click ‘Audio Conference’
Choose ‘I will call in’, select the Toll number.
Dial in using the information from the dialog box that appears.
Be certain to use the Access Code AND the Attendee ID.

Troubleshooting:
If the URL above does not work, go to dukemed.webex.com and enter:
Meeting Number: 120 398 9257
Meeting Password: 1234

For Audio ONLY:
Call-in toll number (US/Canada): 1-650-479-3207
Access code: 120 398 9257

NOTE: For Toll-free users, the call-back (call me) services are also available.

May 14, 2020: Healthcare Workers Invited to Join the HERO Registry

Posted on by Gina Uhlenbrauck

The Healthcare Worker Exposure Response & Outcomes (HERO) Registry invites both clinical and nonclinical healthcare workers to share their life experiences in order to understand the perspectives and problems faced by those on the COVID-19 pandemic frontlines. HERO Registry participants could have the opportunity to participate in future research studies to improve the understanding of COVID-19 and beyond, generating evidence to help healthcare workers stay safe and healthy.

The HERO Registry is open to all healthcare workers, including nurses, therapists, physicians, emergency responders, food service workers, environmental service workers, interpreters, transporters — anyone who works in a setting where people receive health care.

Learn more about the HERO Registry and how to join.

Don’t miss the recent COVID-19 Grand Rounds introducing the HERO Program and get the latest information and resources on COVID-19 for clinical researchers.

May 14, 2020: Healthcare Innovation Highlights Launch of NIH Collaboratory’s EHR Workshop Grand Rounds Series

Posted on by Gina Uhlenbrauck

An article on the Healthcare Innovation website last week highlighted the launch of the NIH Collaboratory’s special Grand Rounds series on electronic health records (EHRs). The article discusses a presentation by Dr. Robert Califf, head of strategy and policy for Verily Life Sciences and Google Health, who envisioned how the healthcare system can learn from innovations being implementing during the COVID-19 emergency. Dr. Califf gave the opening keynote address for the EHR workshop series.

The article mentions the new Healthcare Worker Exposure Response and Outcomes (HERO) registry, funded by the Patient-Centered Outcomes Research Institute (PCORI), and the RECOVERY Trial, a national platform trial in the United Kingdom. Both of these COVID-19 studies were recently featured on NIH Collaboratory Grand Rounds.

Read the full article and hear Dr. Califf’s keynote presentation.

The EHR Workshop Grand Rounds series, Advances at the Intersection of Digital Health, Electronic Health Records and Pragmatic Clinical Trials, will continue on May 29. Previous and upcoming presentations in the series include:

April 15, 2020: NIH Collaboratory COVID-19 Grand Rounds Series Continues With Discussion of HERO Program for Healthcare Workers

Posted on by Damon Seils

The NIH Collaboratory Coordinating Center is using its popular Grand Rounds platform to share late-breaking research and promote resources in support of clinical researchers affected by the COVID-19 public health emergency.

In this week’s COVID-19 Grand Rounds session, leaders of the Patient-Centered Outcomes Research Institute (PCORI) and investigators from the Healthcare Worker Exposure Response and Outcomes (HERO) registry and the HERO-HCQ randomized clinical trial will present “The HERO Program: PCORnet® at Work to Create a Healthcare Worker Community for Rapid Cycle Evidence.” The Grand Rounds session will be held on Friday, April 17, at 1:00 pm eastern. Join the online meeting.

Previous COVID-19 Grand Rounds:

Recent news announcements:

We will continue to share new research, resources, and guidance as they become available.